Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer - Wikidata - awgldk - TriplyDB

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

http://www.wikidata.org/entity/Q26780387

about

Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells Clinical relevance of circulating cell-free microRNAs in ovarian cancer Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.The Clinical Relevance of Beta Blockers in Ovarian Carcinoma: A Systematic Review Association between Body Powder Use and Ovarian Cancer: The African American Cancer Epidemiology Study (AACES)Differential network analysis from cross-platform gene expression data.Identifying differential networks based on multi-platform gene expression data.Characterization of H type 1 and type 1 N-acetyllactosamine glycan epitopes on ovarian cancer specifically recognized by the anti-glycan monoclonal antibody mAb-A4.The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples.Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth.DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer.Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma HOTAIR: a key regulator in gynecologic cancers.Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening.Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients.Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer Mathematical models of breast and ovarian cancers.Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer.Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer.SEOM Clinical Guideline in ovarian cancer (2016)Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.Epigenetic activation of MGAT3 and corresponding bisecting GlcNAc shortens the survival of cancer patients.The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.Analysis of the chemotherapeutic effects of a propadiene compound on malignant ovarian cancer cells.Haploinsufficiency networks identify targetable patterns of allelic deficiency in low mutation ovarian cancer.Preoperative red cell distribution width and neutrophil-to-lymphocyte ratio predict survival in patients with epithelial ovarian cancer Ovarian hormones through Wnt signalling regulate the growth of human and mouse ovarian cancer initiating lesions Similarity and diversity of the tumor microenvironment in multiple metastases: critical implications for overall and progression-free survival of high-grade serous ovarian cancer.Sprouty2 inhibits amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells.Ovarian cancer stem cells: still an elusive entity?Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP.

P2860

Q26738643-B0852660-20D2-4FC2-A562-50A1D4D24F98 Q26747154-ACC05CAE-2994-4FAB-A91E-ABE3A6BC3D90 Q26747279-D87053D6-635F-4342-BDA1-E69B6D5FCA05 Q27333756-C5BC5ADC-DFD4-4A56-8E40-A94969C70614 Q28074666-21941A59-C2C9-40CB-BB47-B2C1B2560CF5 Q30276778-FE48624F-35FA-4DF3-8AE9-EF530C177413 Q31133441-37F28072-146F-4B1A-81CE-0D3EE96A6B1D Q31143551-98884CC8-605D-4CAF-942A-0E5165EB829C Q33564920-E7305EE5-21E1-4570-8BF6-C13753D1E7D6 Q33574500-56379ABF-1D7F-4475-AFAD-ADD29FC86FD8 Q33588273-AE078A9F-26A3-4462-A102-260B5FBCD258 Q33685402-0EE8899C-F8EF-4752-92D0-539D46F0227C Q33689051-3810CB10-93C3-4701-8DA1-D40CF183240B Q33728994-2F4D3640-62B8-4959-B7A2-E13D99343F19 Q33823602-CA46D745-4D7D-40AF-A875-9158A336B8AE Q33827681-84DF22DD-264E-4E97-9D5D-99D5E3075E5E Q36021163-EC503638-9C70-4AA9-AD9D-B8871124DE6F Q36112242-A7C217FE-F57B-42AC-818B-F096C6C37F3B Q36182381-9CB32C62-A63A-499C-BB42-DDCBDCB9C2A1 Q36317366-E1CD4B27-C77A-491E-B57C-081AF560F908 Q36834937-8BCE97DB-7F8E-4914-BE52-8D9E397FBCB5 Q36904012-F465014C-5472-45A9-99AC-07D09B733140 Q37014152-5BC9248B-51BB-475F-A480-65FB7FE4B394 Q37096241-BD0C8B16-B1C3-45DD-BA31-55B46DE23EAF Q37223322-AF3D2290-2436-4ED2-93B6-36CFAC44DD26 Q37330894-DB92BA81-F604-4448-8521-7267254762E3 Q37362776-BB0AAB3F-B6E6-4AB5-A777-191D90549059 Q37456596-2ECF8E5B-50E2-4E3C-96A2-8789787FCA0C Q37475168-E0B691B2-3B64-4D34-839A-9E94268F0E46 Q37545045-AF6A6F1C-378C-42C8-8C5F-6DD4BCF59818 Q37588348-850D57BB-947D-4AC3-A104-F207C12B24A8 Q37631697-85FBF7BA-FD54-4433-8D1A-0047E04B316B Q37636771-DAA81761-CFC2-4DE4-A40A-2FC75DC55D69 Q37651932-8E33EE41-C8A0-4FA8-A4EE-6B9977B18DA4 Q37657622-3FA579A6-FA12-43D5-806D-AE0780EF5F4D Q37662145-84A5BE07-DE7F-4FB5-93E4-03A2FA7BF3CC Q37687582-54F8FFFE-4D0B-4BF2-B6A7-837ADCCA8533 Q37697198-C22FBF43-33BC-45C2-A400-7EB2E80E23DB Q37713683-01D37BA0-C456-4F89-A739-3CE07A08BE1A Q37718693-36BB0D36-4E7A-4E83-BAA0-876C9669E24D

P2860

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

http://www.wikidata.org/entity/Q26780387

description

2015 nî lūn-bûn

@nan

2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

@ast

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

@en

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

@nl

type

label

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

@ast

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

@en

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

@nl

prefLabel

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

@ast

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

@en

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

@nl

P1433

Q26780387-11D17EE4-9970-44FD-95C8-8DCF20457107

P1476

Q26780387-F131176E-7D6F-43EB-A6C3-53E9F0ED03A5

P2093

Q26780387-0DC77E96-532D-4560-A302-EF3F8A52C3BA

Q26780387-23C6501D-1CFA-47E5-BE1F-1D35CEDCD8F0

Q26780387-2441ED33-369B-4158-8DEA-C775A729067A

Q26780387-2471DB64-23D0-44E5-A25E-D719A94DB25D

Q26780387-5A788AC9-84AA-4C5B-9344-7316EA655BD5

Q26780387-61E46811-F0D9-4B50-B6DF-E3B46F91E55A

Q26780387-662E396D-2699-4EC1-9B22-5CBDC161E130

Q26780387-6911F5B0-51F6-4094-9161-75ED459C9D39

Q26780387-745A177D-EFD5-4C63-9B5C-7FD378445CD7

Q26780387-80E112F4-01AF-4436-AAEC-4AA4224ECDFA

P2860

Q26780387-01FA80F7-3C8A-4624-B7B6-CA9D654475DC

Q26780387-039D55DF-853D-4080-BEB1-E5F2E7335DA4

Q26780387-0B308EE0-72C2-4EC5-B71E-6D9F0C373A8C

Q26780387-0DD6CC77-2788-47A7-86C3-DDB731C4EA65

Q26780387-0DED030C-CEFA-4C27-A9FC-B14732B676E0

Q26780387-10523783-8E87-40F6-820A-6BE6963313E1

Q26780387-10ADE654-FF73-4549-B168-F7835F619A62

Q26780387-12895015-BD35-4DE0-B017-E8AA6BA342BE

Q26780387-1540A598-2261-4168-96CA-66D7C85514C7

Q26780387-19116197-1C35-4A1A-A956-6FF839C5F7E5

P2888

Q26780387-3BE3E37C-9FEE-4DA6-8F10-70095CD52DAE

P304

Q26780387-518BF7DF-5CEC-44FF-8D03-54829962193A

P31

Q26780387-4CEA7F7A-5B1D-440E-8C61-63A9FED0156C

P3181

Q26780387-57BD6861-004F-43DC-8A7D-B82BC8358004

P356

Q26780387-226D0A91-21D6-4A75-93EA-0DBCD4139EB0

P407

Q26780387-A293FFEC-82C1-4172-A444-A35B999C46BF

P433

Q26780387-0117CCCC-C30D-4894-88AD-03F41EE0B2C9

P478

Q26780387-3DD5C8EC-74E5-41D3-AF44-74C87EC033E5

P50

Q26780387-0BADD43B-7512-4669-9508-12ADC7497DE0

Q26780387-18787482-0FC1-4F3C-9CEF-15838686346E

Q26780387-1C90A305-C182-4CFE-8934-B585A5DE03B0

Q26780387-2C06B2E7-59EA-4E2D-803C-1E0B17C53DA5

Q26780387-3A7ACFFB-8116-49C2-B835-04A8E9124987

Q26780387-69BC5481-F810-404E-8726-F76D55FEF719

Q26780387-6F921675-0F23-466D-87A4-B22728F4FB02

Q26780387-70EAFCAE-5843-4427-9818-2092F1B62DEB

Q26780387-74EFC17E-D7F8-4C80-8F2E-34A533E22306

Q26780387-7E5788CF-CF3F-4A35-8B44-6AD6CD9E25C9

P577

Q26780387-4F84CB0E-2E34-4961-8AFD-18B7C9DF87C0

P5875

Q26780387-1F8C53FD-9D57-4F1E-8F5C-0AB91E9361B7

P6179

Q26780387-20AA60A3-2980-4C5D-B32C-B7C56251C6EE

P698

Q26780387-96123E5E-8B84-4769-A1B6-306CEC4B82E7

P921

Q26780387-E44274FD-61BB-420B-A9B5-798AF872E88F

P932

Q26780387-8DAF0C88-3EEB-478D-9088-B9D44E0CB202

P3181

P356

P1433

Nature Reviews Cancer

P1476

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

@en

P2093

Ahmed A Ahmed

http://www.w3.org/2001/XMLSchema#string

Allyson Kaye

http://www.w3.org/2001/XMLSchema#string

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

Beth Y Karlan

http://www.w3.org/2001/XMLSchema#string

Charlie Gourley

http://www.w3.org/2001/XMLSchema#string

Clare L Scott

http://www.w3.org/2001/XMLSchema#string

Daniel J Powell

http://www.w3.org/2001/XMLSchema#string

David G Huntsman

http://www.w3.org/2001/XMLSchema#string

Douglas A Levine

http://www.w3.org/2001/XMLSchema#string

Euan A Stronach

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing

Comprehensive molecular portraits of human breast tumours

Effect of Screening on Ovarian Cancer Mortality

Targeted anti-vascular therapies for ovarian cancer: current evidence

Ovarian cancer screening--current status, future directions

The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures

One mouse, one patient paradigm: New avatars of personalized cancer therapy

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

P2888

P304

668-79

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

500373

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NRC4019

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

James D Brenton

Christina Fotopoulou

Frances R Balkwill

P577

2015-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283276385

http://www.w3.org/2001/XMLSchema#string

P6179

1019760275

http://www.w3.org/2001/XMLSchema#string

P698

26493647

http://www.w3.org/2001/XMLSchema#string

P921

P932

4892184

http://www.w3.org/2001/XMLSchema#string